|
|
|
Corporate Profile: Dendreon
| Summary: |
Dendreon is
a focused on the development of targeted therapies
for the treatment of cancer. The Company's innovative
approaches include therapeutic vaccines, monoclonal
antibodies and small molecule product candidates. |
| Address (HQ):
|
1301 2nd Avenue
Seattle, WA 98101 |
| Phone #'s (HQ): |
Main |
(206) 256-4545 |
| Human Resources |
(206) 256-4545 |
| Investor Relations |
(206) 829-1500 |
| Fax #'s (HQ): |
Main |
(206) 256-0571 |
| Human Resources |
(206) 256-0571 |
| Investor Relations |
(206) 256-0571 |
| Financial
information: |
| DNDN |
| Issued United States patents: |
Issued U.S. patents 1976-present: patent
link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
